Pillar oncoReveal Myeloid Sequencing Panel - A

Casandra

Casandra Test Code MP16353Version 1 (DRAFT)

Performing Lab

Lab MPLNLab Test ID G NGS HEME A

Pillar oncoReveal Myeloid Sequencing Panel - A

Clinical Use

Use

This NGS panel for Biopharma identifies somatic mutations in 58 genes frequently mutated in myeloid malignancies, including AML, MPN, MDS, and Myelofibrosis. It aids in the identification of relevant genetic mutations that can inform clinical trial inclusion and research studies, providing insight into disease mechanisms and potential therapeutic targets.

Special Instructions

This test is available for use in clinical trials or research purposes only. Stated turn-around-times are for clinical use only and subject to change based on protocol requirements. Final TATs will be specified in the biopharma study contract. Contact MPLN for expert guidance on test requirements and interpretation.

Limitations

Frozen bone marrow samples are not accepted. Extracted DNA must be isolated in a CLIA-certified lab or equivalent. Concentration and volume must be provided for all DNA samples. The test is for research use only and not for diagnostic purposes. Turnaround times are subject to change based on biopharma protocols.

Test Details

Methodology

NGS (Targeted)

Biomarkers

The test identifies somatic mutations in 58 genes associated with myeloid malignancies, providing data for research use.

Mutation (58 genes)

ABL1ANKD26ASXL1ATRXBCORBCORL1BRAFCALRCBLCBLBCBLCCDKN2ACEBPACSF3RCUX1DDX41DNMT3AETNK1ETV6EZH2FLT3GATA1GATA2GNASHRASIDH1IDH2IKZF1JAK2JAK3KDM6AKITKMT2AKRASMPLNF1NPM1NRASPDGFRAPFH6PIGAPPM1DPTENPTPN11RAD21RUNX1SETBP1SF3B1SMC1ASMC3SRSF2STAG1STAG2TET2TP53U2AF1WT1ZRSR2